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INTRODUCTION 
Ceftazidime (GR 20263) is an investigational cephalosporin anti-
biotic with a broad spectrum of activity. In early in vitro studies, 
antibacterial activity has been demonstrated against most aerobic gram-
1-3 
negative organisms, including Pseudomonas aeruginosa. Harper found 
that it had mean minimum inhibitory concentrations (MICs) against 
Enterobacteriaceae of 0.07-0.5 mG/L with at least 90 percent of the 
isolates sensitive to 8 mG/L or less."*" Phillips et al, compared 
ceftazidime with cefotaxime and moxalactam and demonstrated that 
ceftazidime had MICs similar to the other two antibiotics against 
Enterobacteriaceae, while its MICs against Pseudomonas aeruginosa were 
generally in the 1-4 mG/L range compared with cefotaxime and moxalactam 
2 
MICs of 8-64 mG/L. Like cefotaxime and moxalactam, ceftazidime has 
activity against most gram-positive organisms, but is less active than 
the penicillins and first-generation cephalosporins. Organisms usually 
resistant to ceftazidime include anaerobic bacteria, enterococci, 
3 
methicillin-resistant staphylococci, and Listeria monocytogenes. 
Because of its activity against aerobic gram-negative bacilli, beta-
lactamase-positive and -negative Haemophilus influenzae, Streptococcus 
pneumoniae, and Neisseria meningitidis,"" which are the primary bacterial 
pathogens of meningitis, the drug may have a role in the treatment of 
central nervous system infections. Sakata et al, found that 
ceftazidime penetrated into the cerebrospinal fluid of rabbits with 
experimentally-induced Streptococcus pneumoniae, Haemophilus influenzae 
type b, or Escherichia coli meningitis and achieved cerebrospinal fluid 
4 
bacteriocidal titers that ranged from 1:64 to 1:128. 
Before the pharmacokinetics of a new antibiotic such as ceftazidime 
can be adequately described, an accurate and reliable drug assay must 
be developed. Two methods currently available for ceftazidime determi-
nation include microbiological and high-pressure liquid chromatographic 
5,6 
assays. 
There are several different microbiologic antibiotic assay 
techniques, including agar diffusion, turbimetric, inhibition of pH 
change, and radiometric. The one most commonly used is the agar dif-g 
fusion technique. With this method, nutrient agar plates are innocu-
lated with a specific microbe and then the antimicrobial is placed on 
the plate in a paper disk or some type of reservoir. After an incu-
bation period, zones of inhibition around the antimicrobial are 
measured. By comparing these zones with those produced by various 
standard solutions of the antibiotic, the concentration of the anti-
biotic can be determined. With good technique, this method can give 
8 
sensitive and accurate results. Advantages of this method include 
the need for minimal equipment, the low cost of necessary reagents, 
the capacity to evaluate a large number of samples with minimal ad-
ditional labor, and the fact that only substances with biological 
activity are measured.^ Disadvantages include the long incubation time 
before results can be read, the ability of other antibiotics in the 
g 
sample to interfere with results, and the inability to detect metabo-
lites with no biologic activity.^ 
High pressure liquid chromatography (HPLC) is a versatile chemical 
separation technique which has been used to separate and measure a wide 
3 
array of substances ranging from petrochemicals and pesticides to 
9 
drugs. With HPLC, a small volume of liquid containing the dissolved 
sample is injected into a moving liquid carrier. This mixture flows 
through the chromatographic column, which is packed with adsorbent 
particles. Due to chemical forces, the compounds in the sample adsorb 
onto the column in varying amounts, and an equilibrium is established 
between the column and carrier liquid. Adsorption onto the column 
increases the retention time, and will separate the compounds of 
interest. Eventually the compounds elute one at a time from the 
column. As they emerge, they flow through a sensitive detector which 
detects the compound and allows its concentration to be measured. The 
most commonly used detectors measure ultraviolet light absorptivity, 
refractive index, or electrical conductance. The detector sends 
electrical signals to a chart recorder, which plots the series of peaks 
9 
representing the compounds eluting from the column. Advantages of 
this method for measuring drug concentrations include high sensitivity g 
and specificity, the ability to differentiate between closely related 
compounds,^' ^  the ability to detect very small concentrations of the 
drug,"^ and the short amount of time needed to obtain results. Dis-
advantages include the high cost of the equipment, and the fact that 
the process requires much labor when samples cannot be prepared in ad-
vance and automatically injected into the apparatus (as is the case 
with unstable drugs) . 
The objective of this study was to compare the accuracy of an 
HPLC assay with a microbiological assay in the determination of serum 
ceftazidime concentrations. 
4 
MATERIALS AND METHODS 
Study Design 
An independent party added known concentrations of ceftazidime 
to samples of pooled human serum. These blinded samples were then 
assayed for concentrations of ceftazidime using an agar diffusion 
microbiologic assay and an HPLC assay performed in two separate 
laboratories. The results of the two assays were then compared with 
the known concentrations of the samples. 
HPLC Assay 
Apparatus. The HPLC system consisted of a gradient liquid chroma-
tograph with a fixed wavelength (254 nm) ultraviolet light detector, 
model 332 (Beckman Instruments, Inc., Berkeley, CA), an autoinjector, 
WISP^710B (Waters Associates, Milford, MA), and a chart recorder, 
model 555 (Linear Instruments, Reno, NV). Chromatography was per-
formed on a 100 mm x 4.6 mm stainless steel column packed with 
® 
Hypersil ODS (Allech Associates, Deerfield, IL). 
Internal standard. The internal standard used was hydrochloro-
thiazide obtained from USP Reference Standards, Rockville, MD. 
Sample Preparation. 100 yL of the serum sample were added to 200 uL 
methanol (containing the internal standard) in a conical centrifuge 
tube. This was vortexed for 20 seconds and allowed to stand at room 
temperature for one minute. It was then centrifuged at 2500-3000 rpm 
for 15 minutes, and the supernatant used for the assay. Because of the 
instability of the drug, samples were prepared within 30 minutes of 
injection onto the column. 
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Procedure. 15 pL of sample supernatant were injected onto the 
HPLC column and eluted at a flow rate of 2 mL/min. The mobile phase 
consisted of glacial acetic acid 10 mL, acetonitrile 25 mL, and 
deionized water q.s. ad 1000 mL. The pH was adjusted to 4 with 5N 
sodium hydroxide. A standard curve was prepared using samples con-
taining known concentrations of ceftazidime. Peak heights of hydro-
chlorothiazide and ceftazidime were measured and the curve defined by 
the regression of peak height ratio versus ceftazidime concentration. 
Retention time relative to the solvent front was three minutes for 
the internal standard and five minutes for the ceftazidime. 
Microbiological Assay 
Method. Agar diffusion technique on Petri dishes was used. 
Preparation of solutions. 100 mG ceftazidime powder and 10 mG 
anhydrous sodium carbonate were mixed with 35 mL distilled water. 
Varying amounts of this stock solution were then mixed with pooled 
human serum to make the standard solutions. The standard solutions 
ranged in concentration from 0.625 yG/mL to 30 yG/mL. 
Preparation of assay plates. Oxoid (Bathingstokes, England) 
Antibiotic Medium #2 broth was prepared by adding 20.5 G broth to 1 L 
distilled water. One-half mL of overnight soy broth culture of 
Morganella morganii NTC #235 was added to 18 mL of the antibiotic 
medium broth and the mixture was poured into a 150 mM x 15 mM Petri 
dish and allowed to solidify. Filter paper disks were impregnated with 
20 yL each of ceftazidime solutions and placed on the plates. Each 
plate contained two unknown and four standard solutions of ceftazidime. 
All samples were run in duplicate. The plates were then incubated at 
37°C on a flat, level surface for 4-6 hours and for 16-18 hours. 
Determination of ceftazidime concentrations. The diameter of the 
zone of inhibition around each disk was measured with vernier calipers. 
Exponential regression analysis of zone diameter and corresponding con-
centration of standards was used to plot a regression line on semi-log 
graph paper. The concentrations of the unknown samples were then 
determined by reference to this standard curve. 
Statistical Analysis 
A student's t-test for paired data was used to compare the results 
of each assay with the known concentrations of ceftazidime. 
RESULTS 
HPLC Assay 
The separation of the internal standard and the ceftazidime was 
complete and the chromatograph showed sharp, separate peaks (Figure 1). 
The standard curve was linear with a correlation coefficient of 
0.92 (Figure 2). 
The comparison of drug concentrations determined by the HPLC assay 
versus the known concentrations demonstrated no significant difference 
between the two sets of values (p > 0.05) (Table 1). The maximum per-
centage of difference between any single measurement and the true con-
centration was 12.6 percent. The mean percentage of difference for all 
the samples was 5.1 percent. 
Microbiological Assay 
Comparison of the drug concentrations determined by the micro-
biological assay versus the known concentrations demonstrated a 
significant difference between the two sets of values (p < 0.05) 
(Table 2). The maximum percentage of difference between any single 
measurement and the true concentration was 20.3 percent. The mean 
percentage of difference for all the samples was 10 percent. Results 
from one sample (#11) were not obtained due to technical difficulties. 
The correlation coefficient between the microbiological assay and the 
HPLC assay results was 0.985. 
DISCUSSION 
The purpose of this study was to compare the accuracy of an HPLC 
assay with a microbiological assay in determining serum ceftazidime 
concentrations. In contrast to other work which found no significant 
differences between an HPLC assay and an agar diffusion microbiological 
assay,^ this study found the HPLC assay to be more accurate. The HPLC 
assay produced results that were not significantly different from the 
known concentrations of the samples, while the microbiological assay 
did show statistically significantly different results. The accuracy 
of the microbiological assay ranged from no to 20 percent error for any 
one sample. While this amount of error may be acceptable for routine 
clinical use, it could substantially alter results of pharmacokinetic 
studies. Ceftazidime is an unstable drug in solution and therefore, 
the HPLC assay is labor-intensive in this situation. That, along with 
the high initial cost of an HPLC apparatus, may make a microbiological 
8 
assay more appropriate for routine clinical practice. However, it is 
apparent that some degree of accuracy will be lost if a microbiological 
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TABLE 1. Known Concentrations Versus HPLC Assay Results 
Sample Known Cone. HPLC Assay Difference Percentage 
Number (mG/L) (mG/L) (mG/L) Difference 
1 180 180.2 - 0.2 - 0.1 
2 167 165.2 + 1.8 1.1 
3 150 140.5 + 9.5 6.3 
4 133 136.2 - 3.2 - 2.4 
5 120 116.3 + 3.7 3.1 
6 100 101.0 - 1.0 - 1.0 
7 80 71.0 + 9.0 11.3 
8 67 64.5 + 2.5 3.7 
9 50 43.7 + 6.3 12.6 
10 33 29.4 + 3.6 10.9 
11 20 18.4 + 1.6 8.0 
12 10 10.1 - 0.1 - 1.0 
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TABLE 2. Known Concentrations Versus Microbiologic Assay Results 
Sample Known Cone. Microbiologic Difference Percentage 
Number (mG/L) Assay (mG/L) (mG/L) Difference 
1 180 173 + 7 3.9 
2 167 161 + 6 3.6 
3 150 125 + 25 16.7 
4 133 106 + 27 20.3 
5 120 124 - 4 - 3.3 
6 100 92 + 8 8.0 
7 - 8 0 65 + 15 18.8 
8 67 57 + 10 14.9 
9 50 46 + 4 8.0 
10 33 29 + 4 12.1 
11 20 * * * 
12 10 10 0 0.0 
* No result due to technical difficulties 
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